NCT07218029View on ClinicalTrials.gov

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

815

Participants

Timeline

Start Date

November 14, 2025

Primary Completion Date

December 7, 2028

Study Completion Date

December 7, 2028

Conditions

Pulmonary Arterial Hypertension

Interventions

BIOLOGICAL

Sotatercept

Sotatercept SC injection at a dose of 0.3 to 0.7 mg/kg

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY